Novo Nordisk warns of 2026 sales decline, shares fall

Novo Nordisk forecast 2026 adjusted sales and operating profit to decline 5%–13% at constant exchange rates, citing U.S. price reductions and loss of exclusivity for GLP-1 drugs, sending shares down about 13%. The company cut U.S. cash prices (to $349/month for self-pay) and struck a Medicare supply deal at $245/month with $50 copays; despite the outlook it reported Q4 EPS of $1.02 (vs. $0.92 est.) and revenue of $12.53 billion (vs. $11.99 billion). For 2025 net sales were DKK 309.1 billion (up 6% DKK, 10% CER) and operating profit DKK 127.7 billion; management noted early uptake of the Wegovy oral pill with ~50,000 weekly prescriptions by Jan. 23.

Analysis

Market structure: Novo Nordisk’s guidance (adj. sales/op. profit -5% to -13% in 2026) reweights winners toward payers, Medicare plans, and rivals that can sustain premium pricing (e.g., Eli Lilly). Short-term incumbents of GLP-1 pricing power lose leverage in the US where cash price cuts to $349/mo and Medicare at $245/mo compress per-patient revenue; international growth may offset ~50–70% of US decline depending on uptake. Supply/demand: demand remains strong (Wegovy pill ~50k weekly scripts), so volume growth likely replaces some price-led revenue loss, favoring high-capacity manufacturers and commercial channels. Cross-asset: expect higher NVO equity vol and credit spread widening; pharma sector beta to health insurers (UNH, CVS) may turn positive; dollar FX impact limited but softer NVO could weigh DKK via lower FCF repatriation expectations.

Risk assessment: tail risks include accelerated generic semaglutide entry (timeline surprises), CMS further price negotiations, or class-wide safety reviews that could cut prescriptions sharply; probability low but impact severe. Immediate (days) risk is elevated IV and headline-driven swings; short term (3–6 months) risk centers on script momentum and Q1 2026 updates; long term (12–36 months) risk is loss of exclusivity and margin structural decline. Hidden dependencies: payer formulary moves and one-off Medicare deals set price anchors broadly; physician adoption of the oral pill (starter-dose driven) could either restore pricing leverage or broaden self-pay erosion. Key catalysts: Q1 scripts, CMS guidance, patent litigation outcomes, and competitive launches over next 3–12 months.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio-sized tactical short in NVO via a 3–6 month put spread (debit) to cap premium; size to risk tolerance and aim for profit-taking at 30–40% return or unwind if weekly Wegovy scripts fall >25% from 50k/week within 6 weeks.
• Implement a 1–3% pair trade: long Eli Lilly (LLY) equity (1–3% depending on conviction) and short NVO (1–1.5%) over a 6–12 month horizon to capture likely share gains for tirzepatide; use call spreads on LLY and put spreads on NVO if IV remains elevated.
• Rotate 1–2% into insurers: buy UNH or CVS (equal-weighted) for 3–9 months to capture net-benefit from lower GLP-1 pricing (Medicare deal at $245/mo); sell 3–6 month covered calls to enhance yield while retaining upside to margin improvement.
• Deploy a conservative contrarian long: if NVO trades >20% below pre-drop levels, buy a 12–18 month NVO call spread sized 0.5–1% to play recovery tied to oral Wegovy scaling to >100k weekly scripts by Q3; exit if patent litigation goes against Novo or scripts stall for two consecutive months.
• Monitor triggers to act within 30–90 days: weekly US Wegovy script trajectory (thresholds: 50k current, 100k bullish, <35k bearish), CMS/payer pricing announcements, and Q1 2026 sales commentary; adjust position sizes by ±50% on catalyst confirmation.